Moreover, the WEE1 inhibitor adavosertib alone or in combination with olaparib was assessed in a Phase II study enrolling patients with recurrent ovarian cancer with previous progression on PARPi treatment, approximately half with a germline or somatic BRCA1/2 mutation [111]. The gene discussed is WEE1; the disease is ovarian carcinoma.